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In the postabsorptive state, certain tissues, in-
cluding the brain, require glucose as the sole
source of energy. After an overnight fast, he-
patic glycogen stores are depleted, and gluco-
neogenesis becomes essential for preventing
life-threatening hypoglycemia. Mice with a tar-
geted deletion of KLF15, a member of the
Kru¨ppel-like family of transcription factors, dis-
play severe hypoglycemia after an overnight
(18 hr) fast. We provide evidence that defective
amino acid catabolism promotes the develop-
ment of fasting hypoglycemia in KLF15/
mice by limiting gluconeogenic substrate avail-
ability.KLF15/ liver and skeletal muscle show
markedly reduced mRNA expression of amino
acid-degrading enzymes. Furthermore, the en-
zymatic activity of alanine aminotransferase
(ALT), which converts the critical gluconeo-
genic amino acid alanine into pyruvate, is
decreased (50%) in KLF15/ hepatocytes.
Consistent with this observation, intraperito-
neal injection of pyruvate, but not alanine,
rescues fasting hypoglycemia in KLF15/
mice. We conclude that KLF15 plays an impor-
tant role in the regulation of gluconeogenesis.
INTRODUCTION
Mice deficient in factors that regulate the activity of gluco-
neogenic pathway enzymes (e.g., PEPCK) exhibit fasting
hypoglycemia (Rhee et al., 2003; Koo et al., 2004; Herzig
et al., 2001). However, gluconeogenesis relies upon not
only the appropriate expression/function of key regulatory
enzymes but also a steady supply of small carbon precur-
sors for use as substrate. A major source of substrate isCthe catabolism of muscle protein to amino acids. While
most amino acids are broken down in the liver, the break-
down of leucine, isoleucine, and valine (the branched-
chain amino acids, or BCAAs) in skeletal muscle provides
perhaps the most important source of gluconeogenic sub-
strate, alanine. During fasting, the blood is enriched with
alanine synthesized in skeletal muscle using amino groups
donated from BCAAs. Alanine is the predominant amino
acid released from muscle and taken up by the liver (Felig
et al., 1969), where it is converted to pyruvate and used for
gluconeogenesis (Felig et al., 1970).
The Kru¨ppel-like family of transcription factors is a
subclass of Cys2/His2 zinc-finger DNA-binding proteins.
Kru¨ppel-like factors are critical regulators of growth and
development in a wide variety of tissues (reviewed in
Bieker, 2001; Kaczynski et al., 2003). KLF15 is expressed
in multiple tissues, including liver, white and brown adi-
pose, kidney, heart, and skeletal muscle, with strongest
expression occurring in the liver and kidney (Gray et al.,
2002). KLF15 has previously been shown to regulate the
expression of genes involved in glucose uptake and adi-
pogenesis, such as GLUT4 (Gray et al., 2002) and PPARg
(Mori et al., 2005). To understand the role of KLF15 in the
regulation of glucose homeostasis in vivo, we performed
a targeted deletion of this gene in mice by homologous
recombination (targeting described in Fisch et al., 2007).
KLF15/ mice exhibit severe hypoglycemia after an over-
night (18 hr) fast. To determine the cause of the fasting
hypoglycemia, we first assessed whether alterations in
hepatic glucose production and/or peripheral glucose
disposal contributed to the phenotype. Hyperinsuline-
mic-euglycemic clamp studies showed normal glucose
utilization in peripheral tissues, and no defects were found
in the major mechanisms of hepatic energy production,
including glycogen storage/breakdown, fatty acid oxida-
tion, and expression of gluconeogenic pathway enzymes.
We provide in vivo evidence that in KLF15/ mice, the
gluconeogenic pathway is intact, but inefficient amino
acid catabolism limits the availability of gluconeogenic
substrate.ell Metabolism 5, 305–312, April 2007 ª2007 Elsevier Inc. 305
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KLF15 in GluconeogenesisFigure 1. Glycemic Responses in Wild-Type versus KLF15-Deficient Mice
White bars = wild-type; black bars = KLF15/. Mice are 2.5–3.5 months old unless otherwise stated.
(A) Representative northern analysis ofKLF15 expression in WT (+/+) andKLF15 null (/) tissues using probes against the non-DNA-binding domain
(NDB) and 30 untranslated region (30UTR) of KLF15. Ten micrograms of total RNA was loaded per lane.
(B) Blood glucose levels of WT and KLF15/ mice in the ad libitum-fed or 18 hr-fasted states; n = 15–20 mice per group. In this and all other figures,
error bars represent ± SEM.
(C) Blood glucose concentrations during a glucose tolerance test. Mice were fasted for 16 hr and received an intraperitoneal (i.p.) injection of 1 g
glucose/kg body weight. Tail-vein blood samples were assessed for glucose concentration immediately before injection (time 0) and at 15, 30, 60,
and 120 min postinjection; n = 7–11 mice per group.
(D) Hyperinsulinemic-euglycemic clamp study in WT andKLF15/ 4-month-old male mice. Top left: basal plasma glucose levels after a 5 hr fast. Top
middle: basal hepatic glucose production after a 5 hr fast. Top right: hepatic glucose production during insulin clamp. Bottom left: insulin-stimulated
whole-body glucose turnover. Bottom right: glucose infusion rate during insulin clamp. n = 7 mice per group. Statistical comparisons were made by
repeated-measures ANOVA (C) and Student’s t test for unpaired samples (B–D). *p% 0.05 compared to WT control.RESULTS AND DISCUSSION
Metabolic Phenotype of KLF15-Deficient Mice
Northern analysis of liver and quadriceps skeletal muscle
tissue indicated that KLF15 mRNA is undetectable in
KLF15/ mice (Figure 1A). As shown in Figure 1B, there
was a small but statistically significant decrease in blood
glucose in KLF15/ males and females compared to
same-sex WT controls in the ad libitum-fed state. After
an 18 hr fast, KLF15/ mice show severe hypoglycemia
(male: WT = 102 ± 5.8 mg/dl, KLF15/ = 58 ± 3.2 mg/dl,
p < 0.0001; female: WT = 83 ± 5.2 mg/dl, KLF15/ =
45 ± 2.6 mg/dl, p < 0.0001). Glucose tolerance tests
(GTTs) performed on mice that had been fasted for 16 hr
and had received an intraperitoneal (i.p.) injection of 1 g306 Cell Metabolism 5, 305–312, April 2007 ª2007 Elsevier Inc.glucose/kg body weight indicated that KLF15/ mice
clear glucose more efficiently than WT mice (Figure 1C).
The integrated glucose concentrations, calculated as
area under the curve, were significantly lower in KLF15/
mice compared to WT controls. Serum insulin levels of
WT and KLF15/ mice during a separate GTT were not
significantly different (see Figure S1 in the Supplemental
Data available with this article online), indicating that in-
creased glucose clearance in KLF15/ mice does not
result from enhanced insulin secretion. To directly exam-
ine the effect of KLF15 deficiency on insulin sensi-
tivity, we performed a 2 hr hyperinsulinemic-euglycemic
clamp study (Figure 1D) at an insulin infusion rate of
2.5 mU/kg/min in awake WT and KLF15/ mice in the
postabsorptive state (5 hr after food removal). As shown
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KLF15 in GluconeogenesisFigure 2. Effect of KLF15 Level on Metabolic Enzyme Expression and Serum Amino Acid Concentrations
(A and B) Northern analysis of enzymes of gluconeogenesis and fatty acid oxidation (A) and amino acid catabolism (B) in liver and skeletal muscle
(quadriceps) isolated from 3- to 4-month-old female WT and KLF15/ (KO) ad libitum-fed or 18 hr-fasted mice. Ten micrograms of total RNA
was loaded per lane. Each column represents an individual mouse; two representative mice (out of six total) are shown for each condition. PEPCK,
phosphoenolpyruvate carboxykinase; L-CPT I, liver carnitine palmitoyltransferase 1; M-CPT I, muscle carnitine palmitoyltransferase 1; MCAD,
medium-chain acyl-CoA dehydrogenase; ALT 1, alanine aminotransferase 1; ProDH, proline dehydrogenase; TDO2, tryptophan 2,3-dioxygenase;
HPD, 4-hydroxyphenylpyruvate dioxygenase; OTC, ornithine transcarbamylase; BCAT2, branched-chain aminotransferase 2.
(C) Northern analysis of enzymes of amino acid catabolism in wild-type primary hepatocytes and skeletal myocytes infected with either empty vector
(EV) or KLF15 (K) adenovirus at 30 moi (10-fold overexpression of KLF15).
(D) Serum amino acid levels in ad libitum-fed or 18 hr-fasted WT and KLF15/ mice. Blood was collected from the orbital sinus of 2.5- to 3.5-month-
old female mice, and serum was analyzed for amino acid content using gas chromatography/mass spectrometry (see Experimental Procedures).
White bars = wild-type; black bars = KLF15/. n = 16–20 per group; *p% 0.05 compared to WT control (Student’s t test for unpaired samples).in Figure 1D, KLF15/ mice exhibited a small but statisti-
cally insignificant reduction in hepatic glucose production
(HGP) in the basal state. However, during the insulin
clamp, HGP was reduced by more than 60% in KLF15/
mice compared to WT controls, which resulted in a signif-
icantly elevated glucose infusion rate in the KLF15/
mice. Finally, whole-body glucose turnover rates were
similar in the WT and KLF15/ groups. These results
indicate increased hepatic insulin sensitivity in the
KLF15/ mice and suggest that the enhanced glucose
clearance during the GTT results mainly from reduced
hepatic glucose production rather than increased periph-
eral glucose disposal.
Mechanisms of Decreased Hepatic
Glucose Production
Thus, we focused on potential causes of decreased
hepatic glucose/energy production in order to further un-
derstand the mechanism behind the fasting hypoglycemia
phenotype. As a first step, we determined the mRNA
expression levels of key enzymes involved in fatty acid
oxidation (FAO) and gluconeogenesis in WT andKLF15/ mice. As shown in Figure 2A, the expression
levels of carnitine palmitoyltransferase (CPT I) and me-
dium-chain acyl-CoA dehydrogenase (MCAD), two key
rate-limiting enzymes of FAO, were not decreased in
either liver or skeletal muscle (quadriceps) of KLF15/
mice. In addition, circulating levels of b-hydroxybutyrate
were markedly increased in KLF15/ mice in the fasted
state (Table 1). This hyperketonemia strongly argues
against impaired FAO as a contributor to the hypoglyce-
mia, as the substrate for ketone bodies during fasting is
derived mainly from acetyl-CoA produced by FAO. Free
fatty acid (FFA) levels in fed KLF15/ mice were in-
creased 2-fold compared to fed WT mice (Table 1). While
b-hydroxybutyrate levels were not increased in fed
KLF15/ mice, we consistently observed elevated urine
acetoacetate levels (R160 mg/dl) in both fed and fasted
KLF15/ mice (data not shown). A recent study has
shown that KLF15 induces PEPCK, one of the main rate-
limiting enzymes of gluconeogenesis, in cultured hepato-
cytes (Teshigawara et al., 2005). However, we found
no decrease in the mRNA levels of PEPCK (Figure 2A)
or glucose-6-phosphatase/fructose-1,6-bisphosphataseCell Metabolism 5, 305–312, April 2007 ª2007 Elsevier Inc. 307
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KLF15 in GluconeogenesisTable 1. Metabolic Parameters of Wild-Type and KLF15/ Mice
Fed Fasted
nWT KLF15/ WT KLF15/
Hepatic glycogen content (mg/g liver) 41.09 ± 3.24 40.87 ± 3.17 1.98 ± 0.60 0.57 ± 0.17* 7
FFA (mEq/l) 0.52 ± 0.04 0.97 ± 0.04* 1.11 ± 0.06 1.15 ± 0.05 15–18
b-hydroxybutyrate (mmol/l) 0.28 ± 0.02 0.30 ± 0.03 1.26 ± 0.15 3.04 ± 0.28* 5–10
Glycerol (mg/dl) 0.79 ± 0.05 1.34 ± 0.08* 0.83 ± 0.05 1.68 ± 0.08* 17–20
Lactate (mmol/l) 3.96 ± 0.15 3.05 ± 0.18* 2.18 ± 0.09 1.76 ± 0.07* 17–19
Insulin (ng/ml) 2.78 ± 0.31 2.45 ± 0.28 0.08 ± 0.02 0.06 ± 0.01 12–17
Glucagon (pg/ml) 51.78 ± 2.00 79.47 ± 6.67* 38.05 ± 1.29 54.00 ± 2.84* 10–18
Mice were 3–4 months old for all measurements. Assays of blood samples were performed on isolated serum, except b-hydroxy-
butyrate values, which were determined on whole blood. Values are means ± SEM. *Significantly different compared to WT control
(Student’s t test for unpaired samples; p < 0.05). FFA, free fatty acids; Fed, animals bled or sacrificed between 9:00 and 10:00 a.m.;
Fasted, animals fasted overnight (18 hr).(data not shown) in KLF15/ mice compared to WT mice
in the fed or fasted state. WT and KLF15/ mice showed
no difference in hepatic glycogen content in the fed state;
however, after an 18 hr fast, KLF15/ livers contained
3.5-fold less glycogen than WT controls (Table 1). This
increased capacity for glycogenolysis with fasting may
be a compensatory response to the hypoglycemia. No
significant difference was detected in serum insulin levels
between WT andKLF15/ mice in both the fed and fasted
states, while KLF15/ mice showed increased fed/fasted
glucagon levels, again suggesting a compensatory re-
sponse (Table 1). Importantly, no significant differences
in weight were found between WT and KLF15/ mice
for both males and females at ages 1, 2, 2.5, 3, or
3.5 months (n = 15–20 mice per group; data not shown).
Regulation of Amino Acid-Degrading Enzymes
by KLF15
Affymetrix microarray analyses on liver and skeletal
muscle (quadriceps) mRNA from 18 hr-fasted WT and
KLF15/ mice revealed reduced expression of multiple
genes encoding amino acid-degrading enzymes in
KLF15/ mice (four WT versus four KLF15/ females
[4–5 months old] for each tissue type). Results for several
of these genes were confirmed by northern analyses, as
shown in Figure 2B. In the liver, a strong reduction was
seen in the expression levels of alanine aminotransferase
1 (ALT1), proline dehydrogenase (ProDH), tryptophan
2,3-dioxygenase (TDO2) and 4-hydroxyphenylpyruvic
acid dioxygenase (HPD), which catabolize alanine, pro-
line, tryptophan, and tyrosine, respectively. Notably, there
are two murine isoforms of alanine aminotransferase,
ALT1 and ALT2. Both ALT1 and ALT2 mRNAs are ex-
pressed at high levels in the liver; however, in skeletal
muscle, ALT2 is strongly expressed, while ALT1 is barely
detectable (Jadhao et al., 2004). We found no decrease
in the mRNA level of ALT2 in KLF15/ mice in either liver
or skeletal muscle (data not shown). The mRNA level of mi-
tochondrial branched-chain aminotransferase 2 (BCAT2),
which catalyzes the first step in the oxidation of the308 Cell Metabolism 5, 305–312, April 2007 ª2007 Elsevier IncBCAAs, is greatly reduced in skeletal muscle of KLF15/
mice. Finally,KLF15/ mice showed a dramatic decrease
in the mRNA level of ornithine transcarbamylase (OTC),
one of the six enzymes of the urea cycle (Figure 2B).
Adenovirus-mediated overexpression of KLF15 in WT
primary hepatocytes induced expression of ALT1, ProDH,
TDO2, andHPD. Similarly, overexpression of KLF15 in WT
primary skeletal myocytes induced BCAT2 expression
(Figure 2C). These results suggest that KLF15 regulates
the expression of these genes. The fact that KLF15 over-
expression does not induce OTC (Figure 2C) suggests
that decreasedOTC expression in KLF15/ mice may re-
flect a slowdown in the urea cycle secondary to decreased
amino acid breakdown.
Effect of KLF15 Deficiency on Serum Amino Acid
Concentrations
Given the reduced expression of amino acid breakdown
enzymes in KLF15/ mice, we determined serum amino
acid concentrations using gas chromatography/mass
spectrometry (Figure 2D; isoleucine and tryptophan were
undetectable in this assay). As expected, we found
increased concentrations of several amino acids in
KLF15/ serum, including proline, tyrosine, and the
BCAAs leucine and valine. As with alanine, the formation
of glutamine depends largely upon donation of amino
groups from the breakdown of BCAAs in skeletal muscle.
The decreased levels of glutamine seen in KLF15/ mice
may therefore result from inefficient BCAA catabolism.
Glutamine contributes mainly to renal gluconeogenesis,
a source of glucose secondary to hepatic gluconeogene-
sis (Kida et al., 1978). Thus, reduced circulating levels of
glutamine may contribute to the observed phenotype.
Surprisingly, there was no significant difference in serum
alanine levels between WT and KLF15/ mice in either
the fed or fasted state. One possible explanation for this
finding is that, while reducedBCAT2 expression in skeletal
muscle may decrease alanine production, reduced ALT1
expression in liver may slow the rate of alanine catabolism,
resulting in minimal net change in serum alanine.
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KLF15 in GluconeogenesisFigure 3. Pyruvate and Alanine Utilization In Vivo and ALT Activity and Glucose Production in Primary Hepatocytes
(A and B) 18 hr-fasted WT and KLF15/ (KO) mice each received an i.p. injection of 500 mg/kg sodium pyruvate dissolved in water or osmolarity-
matched 104.5 mg/kg NaCl control solution (A) or 200 mg/kg L-alanine dissolved in 104.5 mg/kg NaCl or 104.5 mg/kg NaCl control solution (B).
Tail-vein blood samples were assessed for glucose concentration immediately before injection (time 0) and at the indicated time points postinjection.
n = 7 mice per condition. Statistical comparisons were made using MANOVA (p% 0.05 was considered significant). p = 0.0318 WT saline versus WT
pyruvate; p = 0.0034 KO saline versus KO pyruvate; p = 0.02647 WT saline versus WT alanine; p = 0.7843 KO saline versus KO alanine.
(C and D) WT (white bars) and KLF15/ primary hepatocytes (black bars) were either uninfected or adenovirally infected at 30 moi with EV or KLF15
constructs (10-fold overexpression of KLF15) and incubated at 37C in glucose production buffer (see Experimental Procedures). The buffer was
removed after 3 hr and assayed for glucose content, and the cell lysate was assayed for ALT activity. n = 4 replicates per group for each assay.
Statistical comparisons were made using Student’s t test for unpaired samples.concentration. This result led to the hypothesis that utiliza-
tion, rather than circulating levels, of alanine may be
decreased in KLF15/ mice.
Alanine Utilization in KLF15-Deficient Mice
Alanine catabolism in the liver involves a one-step conver-
sion of alanine to the gluconeogenic substrate pyruvate
via the enzyme alanine aminotransferase. We reasoned
that if the gluconeogenic pathway were still intact in
KLF15/ mice, then administration of exogenous pyru-
vate would rescue fasting hypoglycemia. However, if
KLF15/ mice have a blunted capacity to convert alanine
to pyruvate, little or no improvement in hypoglycemia
should occur upon administration of alanine. In the first
experiment, 4- to 5-month-old WT and KLF15/ females
were fasted for 18 hr, and both groups received an i.p.
injection of sodium pyruvate (dissolved in water) or an
osmolarity-matched NaCl control solution (Figure 3A). In
a separate experiment (Figure 3B), 4- to 5-month-old WT
and KLF15/ females were fasted for 18 hr, and both
groups received an i.p. injection of L-alanine (dissolved
in NaCl) or NaCl control solution. While WT and KLF15/
mice showed similar glycemic responses to pyruvate,
injection of alanine significantly increased glucose con-Ccentration in WT mice, but not in KLF15/ mice. Thus,
KLF15/ mice are capable of gluconeogenesis but are
significantly less efficient than WT mice at utilizing alanine
as a source of gluconeogenic substrate.
Effect of KLF15 Level on ALT Activity
and Glucose Production
Data from several studies confirm that at high alanine
concentrations, ALT-mediated transamination is the main
step controlling the gluconeogenic flux from alanine
(Groen et al., 1982; Mallette et al., 1969; Burelle et al.,
2000). To determine whether ALT deficiency in KLF15/
mice might be involved in their lack of responsiveness to
alanine, we first assessed the enzymatic activity of ALT
in primary hepatocytes isolated from WT and KLF15/
mice. As shown in Figure 3C, ALT activity was reduced
2-fold in KLF15/ hepatocytes compared to WT hepa-
tocytes. In addition, adenoviral overexpression of KLF15
results in a statistically significant increase in ALT activity
in both WT and KLF15/ hepatocytes. Along with
decreased ALT activity, KLF15/ hepatocytes also
exhibit reduced glucose production compared to WT
hepatocytes (Figure 3D). Glucose production is increased
in WT hepatocytes and rescued to near WT levels inell Metabolism 5, 305–312, April 2007 ª2007 Elsevier Inc. 309
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KLF15 in GluconeogenesisKLF15/ hepatocytes by adenoviral overexpression of
KLF15.
Role of Lactate and Glycerol in Gluconeogenic
Substrate Availability
It is important to consider the role of two other significant
gluconeogenic substrate precursors, lactate and glycerol.
The increase in fed/fasted glycerol levels in KLF15/
mice (Table 1) is likely due to the effect of increased gluca-
gon concentration on adipose tissue lipolysis. The contri-
bution of glycerol to gluconeogenic substrate formation
is relatively minor compared to amino acids or lactate
(Landau et al., 1996). Thus, glycerol is unlikely to play a
major role in the development of fasting hypoglycemia.
However, numerous studies indicate that alanine and
lactate are the major gluconeogenic precursors (Consoli
et al., 1990; Chochinov et al., 1978; Kreisberg et al.,
1970). As shown in Table 1, serum lactate levels are mildly
reduced in KLF15/ mice in both the fed and fasted
states. This may be a secondary effect of reduced skeletal
muscle glycolysis (Connett et al., 1990), but it could also
contribute to lack of gluconeogenic substrate availability.
It is clear, however, that an inability of KLF15/ mice to
efficiently utilize alanine (and other amino acids) will signif-
icantly limit the formation of gluconeogenic substrate.
Amino Acid Catabolism
KLF15/ mice exhibit not only fasting hypoglycemia but
also a significant decrease in blood glucose concentration
in the fed state. This may be due to increased hepatic in-
sulin sensitivity in these mice but could also result from
a decrease in amino acid breakdown, which is an impor-
tant source of energy in both the fed and fasted states
(Jungas et al., 1992). In addition, proton magnetic reso-
nance spectroscopy studies on unanesthetized fed WT
and KLF15/ mice (4-month-old males, n = 6–8 per
group) showed a significant increase in lean mass in
KLF15/ mice compared to WT controls (KLF15/ =
27.11 ± 0.29 g, WT = 23.52 ± 0.70 g; p < 0.0002). This is
also consistent with decreased amino acid breakdown in
KLF15/ mice, as plasma amino acids are known to
both promote the synthesis and inhibit the degradation
of muscle protein (Fulks et al., 1975). KLF15/ mice
show a reciprocal decrease in fat mass compared to WT
controls (KLF15/ = 5.22 ± 0.27 g, WT = 7.70 ± 1.21 g;
p < 0.04), resulting in similar body weight in these mice.
The mechanism by which KLF15 regulates substrate
availability in WT mice during fasting is currently unknown.
One possibility is that KLF15 expression is induced with
fasting, leading to increased expression of amino acid-
degrading enzymes. Teshigawara et al. (2005) find that
the level of KLF15 mRNA in the liver increases by 2-fold
in response to a 24 hr fast. Yamamoto et al. (2004) show
that a 48 hr fast induces KLF15 mRNA expression in skel-
etal muscle by almost 28-fold. Because KLF15/ mice
are hypoglycemic with 18 hr of fasting, we assessed the
level of KLF15 mRNA in liver and skeletal muscle of fed
versus 18 hr-fasted WT mice (n = 4 mice per condition)
via northern analysis/densitometry. KLF15 expression310 Cell Metabolism 5, 305–312, April 2007 ª2007 Elsevier Incwas not significantly increased in liver and showed an ap-
proximately 4-fold increase in skeletal muscle (data not
shown). This may explain why the expression of the liver
amino acid-degrading enzymes shown in Figure 2B
does not increase in 18 hr-fasted versus fed WT mice.
BCAT2 expression in WT skeletal muscle also does not
increase after an 18 hr fast. Although KLF15 levels in skel-
etal muscle have been induced 4-fold at this time, this
induction may not be sufficient to significantly increase
BCAT2 expression. (As shown in Figure 2C, adenoviral
overexpression of KLF15 results in a modest induction
of BCAT2 in primary skeletal myocytes; however, here,
exogenous KLF15 levels represent an 10-fold increase
over endogenous KLF15 levels.)
In general, the fed state is anabolic and the fasted state
is catabolic for amino acids and proteins. However,
Goldberg and Odessey (1972) have shown that increased
utilization of BCAAs in fasted rats is not observed until at
least 24 hr after food removal. Thus, it is possible that dur-
ing the early stages of fasting (<24 hr), basal levels of
amino acid catabolism are sufficient for achieving glucose
homeostasis. As such, the role of KLF15 during an 18 hr
fast may be to maintain, rather than induce, the expression
of amino acid-degrading enzymes. Indeed, the observa-
tions that KLF15 null animals exhibit a marked reduction
in certain amino acid-degrading enzymes and are hypo-
glycemic support the importance of basal amino acid
catabolism. During more prolonged fasting, increased
KLF15 levels may serve to not only sustain but also aug-
ment the expression of amino acid-degrading enzymes,
as shown in our overexpression studies. Finally, we can-
not exclude the possibility that KLF15 may affect the
function of amino acid-degrading enzymes through addi-
tional mechanisms, such as posttranslational modification
or cofactor availability.
Much attention has been focused on the transcriptional
regulation of key gluconeogenic enzymes such as PEPCK
and glucose-6-phosphatase by downstream effectors
of glucagon. (Koo et al., 2005; Yoon et al., 2001; Puig-
server et al., 2003). Much less is known about the
transcriptional regulation of amino acid catabolism, a
process that is critical for efficient gluconeogenesis.
However, a role for PPARa in this process has been
identified (Kersten et al., 2001). The participation of
PPARa in various aspects of lipid catabolism is well
documented (reviewed in Desvergne and Wahli, 1999).
PPARa has now been shown to suppress the expression
of several genes involved in amino acid metabolism,
including urea-cycle enzymes, leading to a decrease
in amino acid degradation. Thus, PPARa and KLF15
appear to perform opposing functions with respect to
amino acid catabolism; any potential relationship between
these two factors remains to be determined. In summary,
KLF15 is the first member of the Kru¨ppel-like family of
transcription factors shown to be important for glucose
homeostasis in vivo. This study identifies KLF15 as a
critical regulator of amino acid catabolism and reveals
an unusual mechanism behind the development of fasting
hypoglycemia..
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Reagents
KLF15 full-length expression vector (pcDNA3.1-KLF15 FLAG) was cre-
ated by PCR amplification of the KLF15 open reading frame using spe-
cific primers that include a FLAG sequence at the 30 end and BglII and
XhoI restriction sites at the 50 and 30 ends, respectively. The cDNA frag-
ment was cut with BglII and XhoI and subcloned into the pcDNA3.1
vector (Invitrogen) digested with BamHI and XhoI. The construct was
verified by DNA sequence analysis and in vitro transcription/transla-
tion. Empty vector (EV) and KLF15 (pcDNA3.1-KLF15 FLAG) adenovi-
ral vectors were prepared by Welgen, Inc.
Animals
KLF15/ mice were generated as described in Fisch et al. (2007).
Homozygous mice were viable/fertile and backcrossed seven genera-
tions onto a C57BL/6 background. Animal care and experiments were
carried out in accordance with both institutional and federal animal
care regulations and were approved by the Harvard Medical Area
Standing Committee on Animals.
Analytical Procedures
Concentrations of amino acids, lactate, and glycerol were measured at
the Mouse Metabolic Phenotyping Analytical Core Facility at Yale Uni-
versity (see Supplemental Experimental Procedures). Glucose levels in
whole blood from the tail vein were determined using a OneTouch Ultra
monitor and glucose test strips from LifeScan. b-hydroxybutyrate
levels were determined in whole blood from the tail vein using a Preci-
sion Xtra monitor and blood b-ketone test strips (Abbott Laboratories,
Medisense Products). Total serum nonesterified fatty acid concentra-
tions were measured using an acyl-CoA oxidase-based colorimetric kit
(Wako NEFA-C, Wako Pure Chemical Industries) at the RIA Core at
Massachusetts General Hospital. Serum insulin concentrations were
determined using an Ultrasensitive Rat Insulin ELISA kit with mouse
standards (Crystal Chem Inc.). Serum glucagon levels were measured
by radioimmunoassay at the Specialized Assay Core at the Joslin
Diabetes Center (Boston).
Determination of Hepatic Glycogen Content
Ten to twenty micrograms of frozen liver tissue was dissolved at 95C
for 30 min in 0.3 ml 0.5 M KOH. Twenty-five microliters of 6% Na2SO4
and 750 ml 100% MeOH were added to cooled samples. Samples were
incubated for 1 hr at 80C and centrifuged at 14,000 rpm at 4C for
5 min. Two hundred microliters of 2 mg/ml amyloglucosidase in
0.2 M sodium acetate buffer (pH 4.9) was added to the pellet for
60 min of incubation at 37C. Ten microliters of sample was used for
glucose assays (GAHK-20 kit, Sigma). Glycogen standard curve was
prepared using glycogen (G1767, Sigma) dissolved in 0.5 M KOH.
Hyperinsulinemic-Euglycemic Clamp/Proton Magnetic
Resonance Spectroscopy
Clamp (see Supplemental Experimental Procedures) and 1H-MRS
studies were performed at the Penn State Mouse Metabolic Phenotyp-
ing Center.
RNA Isolation/Northern Analysis
Total RNA from flash-frozen liver and quadriceps skeletal muscle tissue
or from primary hepatocytes and skeletal myocytes was isolated using
the TRIzol (Invitrogen) method. Ten micrograms per lane was subjected
to gel electrophoresis, blotted onto a nylon membrane, and hybridized
in QuikHyb solution (Stratagene) at 65C with 32P-labeled cDNA probes
acquired from Open Biosystems. 18S oligos purchased from Invitrogen
andKLF15non-DNA-binding domain and 30UTR probes were PCR am-
plified using the KLF15 cDNA clone as a template.
Primary Hepatocyte Studies
Primary hepatocytes were isolated from 3- to 4-month-old female mice
via liver perfusion as previously described (Neufeld, 1997) and platedCat either 4 3 10e6 cells/10 cm dish or 5 3 10 e5 cells/well of a
12-well plate in Williams’ medium E (GIBCO) supplemented with
10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 1 nM insulin,
and 100 nM dexamethasone. Day 1 postisolation, cells were infected
with adenovirus at 30 moi in Williams’ medium E supplemented with
10 mg/ml polybrene. The following day, cells in 10 cm dishes were har-
vested for RNA using the TRIzol method. Glucose production and ALT
activity assay were performed on cells in 12-well plates. Cells were
washed twice with glucose production buffer (GPB; DMEM [no phenol
red, no glucose] + 20 mM sodium lactate, 2 mM sodium pyruvate) and
incubated for 3 hr at 37C in 0.5 ml GPB. GPB was collected and
assayed for glucose using the glucose oxidase method (GAGO-20,
Sigma). ALT activity was measured using the ALT/GPT (UV-Rate) kit
(Stanbio Laboratory, catalog #0930). Briefly, 20 ml of cell lysate was in-
cubated at 37C with 200 ml ALT reagent containing a-ketoglutarate,
DL-alanine, NADH, and LDH. Absorbance at 340 nm was recorded
every minute for 30 min. The slope of absorbance decrease is propor-
tional to ALT activity. One unit of ALT activity was defined as the
amount of enzyme that catalyzes the formation of 1 mmol/l NAD/min
under assay conditions. Protein concentration of cell lysates was
determined using the BCA Protein Assay Kit (Pierce). Final glucose
production and ALT activity values were corrected for protein content.
Primary Skeletal Myocyte Isolation
Hindlimb skeletal muscle was removed from 10-day-old WT C57BL/6
mice, minced in 2.4 U/ml dispase/1% collagenase B/2.5 mM CaCl2, in-
cubated at 37C for 30 minutes, triturated, filtered (Netwell; COSTAR),
and plated 3–4 hr on a non-collagen-coated plate. The suspension was
transferred to a collagen-coated plate and grown in Ham’s F-10
medium + 20% FBS, 13 pen-strep-fungizone, and 2.5 ng/ml bFGF.
Cells were passaged in this medium for 2 weeks and differentiated
by switching to 5% horse serum/DMEM. Differentiated cells were in-
fected with adenovirus at 30 moi for 24 hr and harvested for total
RNA using TRIzol.
Statistical Analysis
Data are expressed as means ± SEM. Results were evaluated by
repeated-measures ANOVA, multivariate analysis of variance
(MANOVA), or Student’s t test for unpaired samples. The difference
was considered to be significant at p% 0.05.
Expression Profiling
Affymetrix microarray analyses were performed at the Harvard
Partners Center for Genetics and Genomics.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, and one figure and can be found with this
article online at http://www.cellmetabolism.org/cgi/content/full/5/4/
305/DC1/.
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